Which of the following supports the good prostate health primarily by maintaining healthy male hormone balance?

a. Lycopene.
b. Horse chestnut seed.
c. Beta-sitosterol.
d. Hyperforin
e. Korean Ginseng

Which of the following supports the good prostate health primarily by maintaining healthy male hormone balance?

a. Lycopene.
b. Horse chestnut seed.
c. Beta-sitosterol.
d. Hyperforin
e. Korean Ginseng

What is the name of the following compound?

I. Phenylacetic acid
II. Benzeneacetic acid
III. α-Toluic acid

a. I only
b. I and II only
c. II and III only
d. All

What is the name of the following compound?

I. Phenylacetic acid
II. Benzeneacetic acid
III. α-Toluic acid

a. I only
b. I and II only
c. II and III only
d. All

Answer: All. Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid) is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor. Because it is used in the illicit production of phenylacetone (used in the manufacture of meth/amphetamine), it is subject to controls in the United States.

Nitration of Benzaldehyde shall yield which of the following?

a. Ortho-Nitrobenzaldehyde
b. Para-Nitrobenzaldehyde
c. Meta-Nitrobenzaldehyde
d. None of the above

Nitration of Benzaldehyde shall yield which of the following?

a. Ortho-Nitrobenzaldehyde
b. Para-Nitrobenzaldehyde
c. Meta-Nitrobenzaldehyde
d. None of the above

Answer:Meta-Nitrobenzaldehyde. The substituent groups that offer meta isomers of the parent compound are know as meta-director. Below is the list of substituents yields meta isomer of the parent compound.

List of Meta-directors:

1. -NO2
2. -SO3H
3. -CHO
4. -CN
5. -N (CH3)3 +
6. -COOH

In the above example, nitration of benzaldehyde will yield meta-nitrobenzaldehyde because the -CHO group present in the ring is a meta director.

Which of the following compounds is Meso Compound?

a. 1-amino-2-methyl-1phenylpropane
b. Glyceraldehyde
c. 2,3-dichlorobutane
d. Chloroiodoethanoic acid

Which of the following compounds is Meso Compound?

a. 1-amino-2-methyl-1phenylpropane
b. Glyceraldehyde
c. 2,3-dichlorobutane
d. Chloroiodoethanoic acid

Answer: 2,3-dichlorobutane. Meso compound is one whose molecules are superimposable on their mirror images even though they contain chiral centers.

A meso compound is optically inactive for the same reason as any other compound whose molecules are achiral: the rotation caused by any one molecule is cancelled by an equal and opposite rotation caused by another molecule that is the mirror image of the first.

It can be easily identified by the fact that one half of the molecule is the mirror image of the other half.

In which of the following its publications, the FDA publishes listing of its biosimilar and interchangeable biological products?

a. Orange Book
b. Red Book
c. Blue Book
d. Purple Book

In which of the following its publications, the FDA publishes listing of its biosimilar and interchangeable biological products?

a. Orange Book
b. Red Book
c. Blue Book
d. Purple Book

Answer: Purple Book. FDA has released the "Purple Book," new documents listing biological products, including all biosimilar and interchangeable biological products licensed by FDA.

The lists include the date a biological product was licensed and whether FDA evaluated the biological product for reference product exclusivity, as defined under the Public Health Service Act.

The Purple Book will also list whether a licensed biological product has been determined to be biosimilar to or interchangeable with a reference biological product.

Separate lists for those biological products regulated by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research are updated periodically.

FDA has recently approved Contrave (Naltrexone hydrochloride and Bupropion hydrochloride extended-release tablets). Contrave is indicated for the treatment of:

a. Management of smoking cessation.
b. Treatment of seizure.
c. Management of chronic weight reduction.
d. Treatment of atypical depression.
e. Management of an opioid abuse.

Answer:

FDA has recently approved Contrave (Naltrexone hydrochloride and Bupropion hydrochloride extended-release tablets). Contrave is indicated for the treatment of:

a. Management of smoking cessation.
b. Treatment of seizure.
c. Management of chronic weight reduction.
d. Treatment of atypical depression.
e. Management of an opioid abuse.

Answer: Management of chronic weight reduction. The U.S. Food and Drug Administration today approved Contrave (Naltrexone hydrochloride and Bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

The most common adverse reactions reported with Contrave include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.

On September 9, 2014, the DEA published a new rule that implements the Secure and Responsible Drug Disposal Act of 2010. This new rule will allow patients to return to pharmacies the drugs they no longer need, and prevent those drugs from being accessed by abusers....

On September 9, 2014, the DEA published a new rule that implements the Secure and Responsible Drug Disposal Act of 2010. This new rule will allow patients to return to pharmacies the drugs they no longer need, and prevent those drugs from being accessed by abusers.

Here are the basics of the rule:

1. Retail and hospital pharmacies, as well as other DEA registrants, may modify their DEA registration to become authorized collectors of unneeded prescription drugs.

2. Registered collectors may operate a collection receptacle at their registered location.

3. Pharmacies may operate collection receptacles at long-term care facilities.

4. Registration as a collector is optional. No pharmacy is required to do this.

For additional information, refer to the DEA Federal Register notice: https://www.federalregister.gov/articles/2014/09/09/2014-20926/disposal-of-controlled-substances.

Which of the following statements are TRUE about S.T.E.P.S. Programs?

I. All prescriptions prescribed under these programs must be filled within 3 days.

II. Prescribe no more than 4 weeks (28 days) of therapy, with no automatic refills.

III. All prescribers must register in the S.T.E.P.S. Prescriber Registry via the Prescriber Registration Card that is located in every S.T.E.P.S. folder.

a. I only
b. I and II only
c. II and III only
d. All

Which of the following statements are TRUE about S.T.E.P.S. Programs?

I. All prescriptions prescribed under these programs must be filled within 3 days.

II. Prescribe no more than 4 weeks (28 days) of therapy, with no automatic refills.

III. All prescribers must register in the S.T.E.P.S. Prescriber Registry via the Prescriber Registration Card that is located in every S.T.E.P.S. folder.

a. I only
b. I and II only
c. II and III only
d. All

Answer:II and III only.

1. S.T.E.P.S. stands for System for Thalidomide Education and Prescribing Safety, a proprietary education and restrictive distribution program for Thalomid (Thalidomide).

The S.T.E.P.S. program was developed because of the toxicity associated with fetal exposure to Thalomid (Thalidomide) and to minimize the chance of fetal exposure to Thalomid (Thalidomide).

2. Thalidomide in combination with Dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma and Erythema Nodosum Leprosum.

3. All prescribers must register in the S.T.E.P.S. Prescriber Registry via the Prescriber Registration Card that is located in every S.T.E.P.S. folder.

4. Only licensed prescribers may register. They should complete, sign, and return the Prescriber Registration Card. Prescriptions cannot be issued by telephone under this program.

5. Prescribers shall not prescribe more than 4 weeks (28 days) of therapy with no automatic refills. A patient shall be informed that all prescriptions must be filled within 7 days (NOT 3 days).

According to Wyoming State Pharmacy Law, a temporary pharmacist license shall not be effective for a period of more than three months from the date of issuance and shall not be renewed.

True or False

According to Wyoming State Pharmacy Law, a temporary pharmacist license shall not be effective for a period of more than three months from the date of issuance and shall not be renewed.

True or False

False, [Wyoming Pharmacy Act 33-24-134(e)].

The Board may issue a temporary pharmacist license according to Wyoming State Pharmacy Law. A temporary pharmacist license shall not be effective for a period of more than six (6) months from the date of issuance and shall not be renewed.

If the prescription is dispensed by an intern, which of the following shall be placed on the label of dispensing container?

I. An initial of dispensing pharmacist.
II. An initial of intern.
III. An initial of preceptor.

a. II only
b. II and III only
c. III only
d. All

Answer:

If the prescription is dispensed by an intern, which of the following shall be placed on the label of dispensing container?

I. An initial of dispensing pharmacist.
II. An initial of intern.
III. An initial of preceptor.

a. II only
b. II and III only
c. III only
d. All

Answer: An initial of preceptor is required, [Wyoming Pharmacy Act, 33-24-136(a)].

(a). Every person who prepares, compounds, processes, packages or repackages, dispenses, fills or sells or offers for sale, at retail or in connection with operation of a health care facility, any prescription, shall place the written memorandum of the prescription in a separate file marked and kept for that purpose, and shall affix a label to the container in which the prescribed substance is dispensed bearing

a. the name and address of the pharmacy and initials of the dispensing pharmacist,

OR

b. of the preceptor if the dispenser is an intern,

c. the date on which the prescription is filed in the pharmacy's files,

d. the name of the person who prescribed the substance,

e. the name of the patient or customer for whom the prescription was made and

f. directions for use by the patient as directed on the prescription by the prescriber.